Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Abstract Purpose: Loss of function of PTEN is a frequent event in melanoma, particularly in tumors with BRAFV600 mutations. The prevalence, pathologic features, and clinical outcomes associated with PTEN loss in patients with stage IIIB/C melanoma were interrogated to improve our understanding …
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S3. Clinical outcomes by PTEN status in patients with BRAF V600 mutations
Accès ouvert
2023
supplementary-materials
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Supplemental figure legends. Legends for supplemental figures
Accès ouvert
2023
supplementary-materials
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Supplementary Figure 1. Representative images of PTEN IHC results in FFPE melanoma tissue samples.
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Figure S2. Flow of samples
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S4. Clinical outcomes by PTEN status in patients without BRAF V600 or NRAS mutations
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S1. Demographics, tumor characteristics, and clinical outcomes by tumor mutation status
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S2. Multivariate analysis of overall survival and time to CNS metastasis in all stage IIIB/C melanoma patients
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Abstract Purpose: Loss of function of PTEN is a frequent event in melanoma, particularly in tumors with BRAFV600 mutations. The prevalence, pathologic features, and clinical outcomes associated with PTEN loss in patients with stage IIIB/C melanoma were interrogated to improve our understanding …
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S3. Clinical outcomes by PTEN status in patients with BRAF V600 mutations
Accès ouvert
2023
other
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Table S2. Multivariate analysis of overall survival and time to CNS metastasis in all stage IIIB/C melanoma patients
Accès ouvert
2023
supplementary-materials
OpenAlex
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael T. Tetzlaff et autres
Supplementary Figure 1. Representative images of PTEN IHC results in FFPE melanoma tissue samples.